{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:58:53Z","timestamp":1771657133204,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00277-019-03645-7","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T20:22:35Z","timestamp":1551471755000},"page":"1999-2001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma"],"prefix":"10.1007","volume":"98","author":[{"given":"Ryo","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Kawajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eijiro","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"8","key":"3645_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"issue":"14","key":"3645_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O\u2019Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"issue":"1","key":"3645_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N Donk van de","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F (2018) CD38 antibodies in multiple myeloma: back to the future. Blood 131(1):13\u201329. \n                    https:\/\/doi.org\/10.1182\/blood-2017-06-740944","journal-title":"Blood"},{"issue":"Suppl 2","key":"3645_CR4","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"L Drgona","year":"2018","unstructured":"Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M (2018) ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24(Suppl 2):S83\u2013S94. \n                    https:\/\/doi.org\/10.1016\/j.cmi.2018.03.022","journal-title":"Clin Microbiol Infect"},{"key":"3645_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/ejh.13164","volume":"101","author":"N Lavi","year":"2018","unstructured":"Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H (2018) Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol 101:699\u2013702. \n                    https:\/\/doi.org\/10.1111\/ejh.13164","journal-title":"Eur J Haematol"},{"key":"3645_CR6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.clml.2018.10.002","volume":"19","author":"KA Frerichs","year":"2018","unstructured":"Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N (2018) Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk 19:e9\u2013e11. \n                    https:\/\/doi.org\/10.1016\/j.clml.2018.10.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"3645_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/ejh.12551","volume":"96","author":"T Hasegawa","year":"2016","unstructured":"Hasegawa T, Aisa Y, Shimazaki K, Ito C, Nakazato T (2016) Cytomegalovirus reactivation in patients with multiple myeloma. Eur J Haematol 96(1):78\u201382. \n                    https:\/\/doi.org\/10.1111\/ejh.12551","journal-title":"Eur J Haematol"},{"issue":"3","key":"3645_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384\u2013394. \n                    https:\/\/doi.org\/10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"issue":"4","key":"3645_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/rmv.655","volume":"20","author":"MJ Cannon","year":"2010","unstructured":"Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20(4):202\u2013213. \n                    https:\/\/doi.org\/10.1002\/rmv.655","journal-title":"Rev Med Virol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03645-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:05:44Z","timestamp":1582934744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["3645"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03645-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"26 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}